OGA

NORTHSHORE HEALTH CENTERS ANNOUNCES MERGER WITH OBSTETRICAL & GYNECOLOGICAL ASSOCIATES

Retrieved on: 
Martedì, Aprile 23, 2024
OGA, North, Woman, Chiropractic, Private practice, Insurance, Obstetrics, Patient, Mental health, Physician, Practitioner, Pharmacy, Nursing

MUNSTER, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NorthShore Health Centers and Obstetrical & Gynecological Associates have merged to create a more comprehensive healthcare experience for patients throughout the region, it was announced today.

Key Points: 
  • MUNSTER, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NorthShore Health Centers and Obstetrical & Gynecological Associates have merged to create a more comprehensive healthcare experience for patients throughout the region, it was announced today.
  • Northshore currently has more than 20 locations between full-service clinics and primary care clinics in local school districts that provide medical, dental, vision, chiropractic, mental health and medication assistance through on-site pharmacies.
  • The new locations will enable the company to provide accessible care to a wider patient base.
  • OGA Valparaiso office, which offers advanced obstetrical and gynecological care throughout Northwest Indiana, is staffed with female doctors, nurse practitioners and midwives and has been operating for more than 50 years.

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Lunedì, Marzo 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Lunedì, Marzo 4, 2024
OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Mercoledì, Marzo 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Mercoledì, Marzo 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Arrcus Joins the Ultra Ethernet Consortium to Accelerate Innovation in Data Center Networking for AI and HPC

Retrieved on: 
Martedì, Dicembre 19, 2023
5G, Software, Internet, Artificial Intelligence, Web3, Technology, Philanthropy, Foundation, Architecture, ARCOS-1, UEC, AI, GPU, HPC, OGA, Linux Foundation, Algorithm, Internet service provider

The UEC is a collaborative effort among industry leaders to address the growing demands of AI and HPC workloads on data center networks.

Key Points: 
  • The UEC is a collaborative effort among industry leaders to address the growing demands of AI and HPC workloads on data center networks.
  • Arrcus is joining the UEC to contribute its expertise in advanced networking technologies, including its Leaf-Spine Fabric Architecture and its support for high-speed Ethernet interfaces, such as 400GE and 800GE.
  • “We are thrilled to join the UEC and contribute to the development of next-generation Ethernet technologies for AI and HPC,” said Shekar Ayyar, chairman and CEO at Arrcus.
  • As Arrcus embarks on this new chapter with the Ultra Ethernet Consortium, the company is poised to play a significant role in shaping the future of Ethernet-based solutions, particularly in the dynamic realms of AI and HPC workloads.

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Lunedì, Dicembre 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Lunedì, Dicembre 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

U.S. Department of Veterans Affairs Awards Acentra Health $52.3M Financial Services Center Contract for Claims Adjudication, Provider Access, Data Analytics and Visualization

Retrieved on: 
Martedì, Ottobre 3, 2023
VHA, Partnership, Office of Inspector General, U.S. Department of Health and Human Services, Air Force Financial Services Center, Veterans Health Administration, U.S. Department of Veterans Affairs, Office of Inspector General, Organization, Trust, CNSI, OGA, FSC, Veteran

MCLEAN, Va., Oct. 03, 2023 (GLOBE NEWSWIRE) -- The U.S. Department of Veterans Affairs (VA) has awarded Acentra Health (formerly CNSI) a three-year, $52.3 million contract to support claims adjudication, provider access, data analytics, and visualization for its Financial Services Center (FSC).

Key Points: 
  • MCLEAN, Va., Oct. 03, 2023 (GLOBE NEWSWIRE) -- The U.S. Department of Veterans Affairs (VA) has awarded Acentra Health (formerly CNSI) a three-year, $52.3 million contract to support claims adjudication, provider access, data analytics, and visualization for its Financial Services Center (FSC).
  • The contract builds on Acentra Health’s existing body of technology-enabled services and solutions work for the FSC, dating back to 2017.
  • The new rules helped reduce manual claims review by department staff, resulting in a 98% reduction of the FSC’s claims backlog.
  • Under the terms of the contract, Acentra Health will continue providing its platforms and services to FSC and its stakeholders, which include the Veterans Health Administration (VHA) and Other Governmental Agencies (OGA).”

SUPCON Intelligent Operation Management & Control System and Hobré Analyzers Receives Rave Reviews at OGA 2023

Retrieved on: 
Lunedì, Settembre 18, 2023
APL, Software as a service, SAMSON, HRC, COVID-19, Artificial intelligence of things, PTTEP, HQC, Gas, Control System, Acquisition, Machine learning, Petronas, Kuala Lumpur Convention Centre, ExxonMobil, DCS, Industrial, OGA, Intelligence, KLCC, Safety, Automation, Consumer electronics

SUPCON showcased its star products and solutions for oil, gas & petrochemical industry, including the Intelligent Operation Management & Control System featured with Ethernet-to-Field network and Industrial Operating System equipped with SaaS APP, as well as the cutting-edge instruments including Hobré analyzers.

Key Points: 
  • SUPCON showcased its star products and solutions for oil, gas & petrochemical industry, including the Intelligent Operation Management & Control System featured with Ethernet-to-Field network and Industrial Operating System equipped with SaaS APP, as well as the cutting-edge instruments including Hobré analyzers.
  • Visitors displayed great enthusiasm towards the SUPCON Intelligent Operation Management & Control System, recognizing its game-changing potential to revolutionize industrial practices in autonomous operation.
  • Another highlight of the SUPCON booth at OGA 2023 was Hobré analyzers.
  • The OGA 2023 event provided a valued platform for the oil, gas & petrochemical industry professionals to have in-depth communications sparking with significant insights.